Candel Therapeutics, Inc. (CADL)Healthcare | Biotechnology | Needham, United States | NasdaqGM
9.64 USD
+0.15
(1.581%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 9.64 |
Hot Take ↕ | July 11, 2026, 6:15 a.m. EDT
The immediate outlook is cautiously bullish driven by a confluence of insider activity and technical momentum. Management is aggressively aligning interests by granting executives and directors substantial option packages, signaling deep internal confidence in the upcoming commercial milestones. This sentiment is echoed by the price action, which has rallied nearly 12% over the last two weeks, breaking out above the 50-day moving average. However, the long-term picture remains precarious; despite a massive 400% surge in 2024, the company is still burning cash with negative free flow and no revenue, relying entirely on future catalysts to sustain valuation. The lack of a dividend and the speculative nature of the biotech sector mean this is a high-risk momentum play rather than a stable investment. |
| Model | MAE |
|---|---|
| MSTL_83_104 ✓ | 0.268400 |
| MSTL_104 | 0.287743 |
| MSTL | 0.460658 |
| AutoTheta | 0.460892 |
| AutoETS | 0.466122 |
| AutoARIMA | 0.473311 |
| MSTL_83 | 0.485262 |
Forecast horizon: 60 days | Selected: MSTL_83_104
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 5.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.012 |
| Excess Kurtosis | -0.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 35.696 |
| Market Cap | 706,325,120 |
| Forward P/E | 43.82 |
| Beta | -0.51 |
| Website | https://www.candeltx.com |
As of July 11, 2026, 6:15 a.m. EDT: Speculators are positioning for a volatile breakout above $11, evidenced by heavy call volume at the $11 strike across multiple expirations and significant put buying at the $10 level. The imbalance in open interest suggests a bet on a sharp move away from the current $9.50 range, likely targeting the $11 resistance or testing the $4 support if the rally fails.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.4758942 |
| Address1 | 117 Kendrick Street |
| Address2 | Suite 450 |
| All Time High | 14.78 |
| All Time Low | 0.66 |
| Ask | 11.86 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 1,967,160 |
| Average Daily Volume3 Month | 2,141,649 |
| Average Volume | 2,141,649 |
| Average Volume10Days | 1,967,160 |
| Beta | -0.511 |
| Bid | 7.08 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 1.884 |
| City | Needham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.64 |
| Current Ratio | 28.046 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 9.865 |
| Day Low | 9.19 |
| Debt To Equity | 35.696 |
| Display Name | Candel Therapeutics |
| Earnings Timestamp | 1,778,761,800 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -55,581,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.089 |
| Enterprise Value | 560,762,112 |
| Eps Current Year | -0.87333 |
| Eps Forward | 0.22 |
| Eps Trailing Twelve Months | -1.01 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.5684 |
| Fifty Day Average Change | 1.0716 |
| Fifty Day Average Change Percent | 0.12506418 |
| Fifty Two Week Change Percent | 47.58942 |
| Fifty Two Week High | 11.36 |
| Fifty Two Week High Change | -1.7199993 |
| Fifty Two Week High Change Percent | -0.15140839 |
| Fifty Two Week Low | 4.35 |
| Fifty Two Week Low Change | 5.2900004 |
| Fifty Two Week Low Change Percent | 1.2160921 |
| Fifty Two Week Range | 4.35 - 11.36 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,392,600,000 |
| Float Shares | 56,808,614 |
| Forward Eps | 0.22 |
| Forward P E | 43.818184 |
| Free Cashflow | -37,903,876 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15531 |
| Held Percent Institutions | 0.5991 |
| Implied Shares Outstanding | 73,270,239 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-27 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. |
| Long Name | Candel Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 706,325,120 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_37378731 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -54,422,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 693,869,163 |
| Number Of Analyst Opinions | 7 |
| Open | 9.75 |
| Operating Cashflow | -47,732,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 916 5445 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 9.64 |
| Post Market Time | 1,783,981,119 |
| Previous Close | 9.49 |
| Price Eps Current Year | -11.038211 |
| Price Hint | 2 |
| Price To Book | 5.116773 |
| Profit Margins | 0.0 |
| Quick Ratio | 27.632 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.150001 |
| Regular Market Change Percent | 1.58062 |
| Regular Market Day High | 9.865 |
| Regular Market Day Low | 9.19 |
| Regular Market Day Range | 9.19 - 9.865 |
| Regular Market Open | 9.75 |
| Regular Market Previous Close | 9.49 |
| Regular Market Price | 9.64 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,619,184 |
| Return On Assets | -0.23642 |
| Return On Equity | -0.51172 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 73,270,239 |
| Shares Percent Shares Out | 0.2202 |
| Shares Short | 16,135,706 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 14,163,766 |
| Short Name | Candel Therapeutics, Inc. |
| Short Percent Of Float | 0.2868 |
| Short Ratio | 7.19 |
| Source Interval | 15 |
| State | MA |
| Symbol | CADL |
| Target High Price | 29.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 20.28571 |
| Target Median Price | 23.0 |
| Total Cash | 194,834,000 |
| Total Cash Per Share | 2.659 |
| Total Debt | 49,271,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.01 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.227375 |
| Two Hundred Day Average Change | 3.4126253 |
| Two Hundred Day Average Change Percent | 0.5480038 |
| Type Disp | Equity |
| Volume | 1,619,184 |
| Website | https://www.candeltx.com |
| Zip | 2,494 |